Shares of Divi’s Laboratories Ltd fell sharply by 6.11% to ₹5,410.60 on Friday, down ₹352.40 from the previous close of ₹5,763.00, after U.S. President Donald Trump signaled his administration is considering imposing tariffs on pharmaceutical imports.
Although pharmaceutical products were temporarily exempt from the earlier round of reciprocal tariffs, Trump’s fresh remarks on Air Force One signaled renewed risks. “Pharma tariffs are going to come in at levels you haven’t really seen before. We are looking at pharmaceuticals as a separate category. We will be announcing that sometime in the near-future and not too distant future. It’s under review right now,” he said.
While pharmaceutical products were temporarily spared in the initial round of reciprocal tariffs, Trump’s latest comments have reignited concerns that the sector may soon be impacted. He warned that drugmakers must return manufacturing to the U.S. or face a “big tax,” unsettling investor sentiment.
Divi’s, which exports a significant portion of its products to the U.S., is particularly sensitive to such policy risks. The company’s current market capitalization stands at ₹1.44 lakh crore, with a P/E ratio of 69.88 and a dividend yield of 0.55%. On Friday, the stock traded in the range of ₹5,428.00 to ₹5,762.65, with an average volume of 300.15K shares.
Trump’s remarks echo previous warnings of a potential 25% tariff on imported medicines. Although no final decision has been made, the lingering uncertainty has renewed selling pressure on Indian pharmaceutical stocks like Divi’s Laboratories.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Please consult your financial advisor before making any investment decisions.
